Climb Bio Inc (CLYM)
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for patients with immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody being studied for B-cell mediated diseases, including primary membranous nephropathy and immune thrombocytopenia in Phase 2 trials, as well as systemic lupus erythematosus in a Phase 1b study. The company is also advancing CLYM116, a preclinical anti-APRIL monoclonal antibody being evaluated for IgA nephropathy and other B-cell mediated diseases. Formerly known as Eliem Therapeutics, Inc., the company adopted the Climb Bio name in October 2024. Climb Bio was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CLYM
|
$12.55
|
-1.0% Downside
|
Fair
|
$20.93
|
65.2% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-13.7x
|
4.9x
|
—
|
699.7 M
|
578.5 M
|
0.1%
|
72.4%
|
94.7
|
—
|
101.3%
|
